A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Takeda
Astex Pharmaceuticals, Inc.
King's College Hospital NHS Trust
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Deciphera Pharmaceuticals, LLC
Celgene
University of Liege
BTG International Inc.
Oxford University Hospitals NHS Trust
Celgene
Centre Hospitalier Universitaire de Saint Etienne
Bayer
Massachusetts General Hospital
Celgene
National Cancer Institute (NCI)
Celgene
Dartmouth-Hitchcock Medical Center
University Health Network, Toronto
GlaxoSmithKline
Amgen
Amgen
Bayer
Poitiers University Hospital
University Hospital Birmingham
Pierre Fabre Medicament
Novartis
PETHEMA Foundation
Merck Sharp & Dohme LLC
AstraZeneca
Merck KGaA, Darmstadt, Germany
Astellas Pharma Inc
National Cancer Institute (NCI)
Newron Pharmaceuticals SPA
National Institute of Allergy and Infectious Diseases (NIAID)
Austrian Forum Against Cancer
National Institutes of Health Clinical Center (CC)
Kaiser Permanente